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E d i t o r i a l
In year 2001, there are over 4900 patients on renal
replacement therapy (RRT) according to data of the Hong
Kong Renal Registry. About 1500 are on transplant and
about 3400 are on dialysis.
In this issue, Choy et al (1) published a very important
paper using Hong Kong Renal Registry data about
patients on RRT who are diabetics.
A recent survey of 149 806 non-institutionalized adults
aged 18 years or older in the United States (US) showed
that the prevalence of diabetes mellitus (DM) rose from
4.9% in 1990 to 6.5% in 1998, with an increase of 33%
(2). Increases were observed in both sexes, all ages, all
ethnic groups, all education levels, and nearly all states
in US. The prevalence of DM in Asian-Pacific region as
well as Hong Kong is also in the increasing trend (3).
The age-standardized prevalence of DM in Hong Kong
was 7.7% in 1990 and 8.9% in 1995. The same rate in
Taiwan was 11% in 1995 and 8.1% in Singapore in 1992
(3). It is these alarming figures making us worry about
the future medical burden that the society will face with
DM patients. In addition, the economic burden of DM
in the society will increase. In 1997, the total medical
expenditure in US incurred by diabetic patients was US$
10 071 per capita, compared with US$ 2669 for the non-
diabetic population (4).
Hong Kong Renal Registry data, as summed up by Choy
et al (1), showed that the prevalence of RRT for DM
patients was 151 per million populations. In year 2000,
DM nephropathy accounted for 29% of all new patients
on RRT in Hong Kong.
Patients with DM are having not only a higher chance of
developing renal failure; once they are on RRT, they have
more significant cardiovascular complications. In Hong
Kong, DM patients have higher chance of experiencing
hypertension (85%), ischemic heart disease (24%),
cerebrovascular disease (9%), and peripheral vascular
disease (3%). A prospective cohort of 270 continuous
ambulatory peritoneal dialysis (CAPD) patients (25.9%
of whom were DM patients) in Hong Kong found that
the presence of DM would incur an increased relative
mortality risk of 2.11 for prevalent CAPD cases (5). This
is also represented in the Registry data by the annual
crude mortality rate of DM patients on RRT at 16 %
compared with non-DM patients on RRT at 6 % (1). Fried
et al (6) found that hospitalization rates in PD patients
were higher among DM (2.2 admissions per patient year)
than non-DM (1.6 admissions per patient year)
populations. Thus it is, once again, confirmed that both
morbidity and mortality are higher among RRT patients
with DM than those without.
As nephrologists and general physicians, we should aim
at three strategies to tackle this major problem:
1. Primary and secondary prevention of diabetic
complications by optimal glycemic control–a
computer analysis of the Diabetes Control and
Complications Trial (DCCT) found that improved
glycemic control resulted in a mean 7.7 additional
years of sight, 5.8 additional years free from end-stage
renal disease, 5.6 additional years free from lower-
extremity amputation, and 15.3 additional years free
from onset of substantial microvascular or neurological
complications (7,8). Similar outcomes among
individuals with type 2 diabetes were demonstrated
in the United Kingdom Prospective Diabetes Study
(9).
2. Secondary prevention of diabetic nephropathies
through other measures–strict blood pressure control
(10), use of angiotensin-converting enzyme (ACE)
inhibition in both incipient and overt diabetic
nephropathies (11,12), normalization of hyper-
lipidemia (13), and the recent findings of angio-
tensin II receptor antagonists in renoprotective effects
in type 2 diabetes (14-16) were all useful in reducing
the progression to nephropathy or renal failure.
3. Prevention of cardiovascular complications in DM
patients on RRT–Parfrey (17) showed that DM is an
independent risk factor of symptomatic de novo
ischemic heart disease in dialysis patients, with an
adjusted relative risk of 3.97. Dialysis patients with
DM have an increased cardiovascular mortality as well
as overall mortality than those without. The excessive
cardiac morbidity and mortality of diabetic patients
on dialysis therapy seem to be mediated via ischemic
disease, rather than progression of cardiomyopathy
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(18). There is a whole list of risk factors for cardio-
vascular disease in dialysis (17,18), which includes
genetics-like presence of the ACE D allele (19),
inflammation, and malnutrition (20). Several strategies
in treating and preventing cardiovascular diseases in
RRT patients with DM encompass blood pressure
control, lipid control, judicious use of aspirin, cessation
of smoking, moderate level of physical activity for 30
minutes per day in most days of the week, as well as
management of left ventricular hypertrophy and
hypoalbuminemia (17-20).
The usefulness of laboratory research in preventing
progression to renal failure cannot be emphasized more.
One aspect may be the use of 3-hydroxy-3methylglutaryl
coenzyme A (HMG-CoA) reductase inhibitor, as shown
in this issue’s original article by He et al (21). They
showed the presence of the antiproliferative property of
NK-104, a new synthetic HMG-CoA reductase inhibitor,
on the mesangial cells (21). This suggests that some
HMG-CoA reductase inhibitor can suppress mesangial
cell proliferation and prevent subsequent development
of matrix expansion in progressive glomerular diseases
in vivo. It is through these research findings that we have
more data on the beneficial effects of drugs on preventing
progression of nephropathies, some of which maybe
applicable to diabetic patients.
Of course, primary prevention in the society is equally
important in reducing the incidence of DM. These include
weight reduction and exercise, which require more on
health education and the change of lifestyles. In many
cases, diet and exercise have controlled blood glucose
levels to the normal range, reversed the course of the
disease, and reduced the risk for accelerated vascular
disease (22).
Prevention is always more important than treatment, and
we, as nephrologists, should advocate with action the
significance of early detection and treatment of
complications of DM, making use of the evidence and
strategies stated above. As yet, there are trends that
diabetes-related complications are on the rise, with US
being an example, despite the fact that doctors are aware
of the potential of prevention. It is either the physicians
or nephrologists not following strategies strictly, or the
patients not doing what they are advised or treated. Thus,
all the more important is the stress of compliance in
patients in ensuring our targets being reached-the targets
of glycemic control, blood pressure control, lipid control,
diet control, and lifestyle changes. All these time and
efforts that we spend will pay out when there will be
less DM patients in the society, and less DM patients
suffering from the complications either before or even
after they have renal failure. Still a long way to go if we
do not put effort into more action now!
Philip Kam-Tao Li
Editor-in-Chief
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